Akero Therapeutics Inc (NASDAQ: AKRO) closed the day trading at $29.31 down -6.00% from the previous closing price of $31.18. In other words, the price has decreased by -$1.87 from its previous closing price. On the day, 1670032 shares were traded.
Ratios:
For a better understanding of AKRO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.27 and its Current Ratio is at 29.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on September 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $69.
On August 28, 2023, UBS started tracking the stock assigning a Buy rating and target price of $83.
Morgan Stanley Upgraded its Equal-Weight to Overweight on January 27, 2023, whereas the target price for the stock was revised from $40 to $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Cheng Andrew sold 75,000 shares for $32.87 per share. The transaction valued at 2,465,063 led to the insider holds 591,416 shares of the business.
Yale Catriona sold 20,646 shares of AKRO for $732,727 on Mar 04 ’24. The Chief Development Officer now owns 78,415 shares after completing the transaction at $35.49 per share. On Dec 27 ’23, another insider, Young Jonathan, who serves as the Chief Operating Officer of the company, sold 5,414 shares for $24.00 each. As a result, the insider received 129,936 and left with 185,131 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 1.75B and an Enterprise Value of 1.23B.
Stock Price History:
Over the past 52 weeks, AKRO has reached a high of $58.38, while it has fallen to a 52-week low of $11.25. The 50-Day Moving Average of the stock is 23.38, while the 200-Day Moving Average is calculated to be 33.03.
Shares Statistics:
Over the past 3-months, AKRO traded about 1.37M shares per day on average, while over the past 10 days, AKRO traded about 2.76M shares per day. A total of 55.75M shares are outstanding, with a floating share count of 48.33M. Insiders hold about 14.15% of the company’s shares, while institutions hold 101.47% stake in the company. Shares short for AKRO as of Feb 15, 2024 were 8.89M with a Short Ratio of 6.49, compared to 7.6M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.97% and a Short% of Float of 16.40%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$1 for the current quarter, with a high estimate of -$0.79 and a low estimate of -$1.15, while EPS last year was -$0.55. The consensus estimate for the next quarter is -$1, with high estimates of -$0.8 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$3.3 and -$5.1 for the fiscal current year, implying an average EPS of -$4.12. EPS for the following year is -$4.49, with 6 analysts recommending between -$3.84 and -$5.4.
